Bristol-Myers Squibb Company (BMY)
Bristol Myers Squibb (BMY) Declines More Than Market: Some Information for Investors
Bristol Myers Squibb (BMY) reached $63.75 at the closing of the latest trading day, reflecting a -1.02% change compared to its last close.
BMY Gains 19.4% Year to Date: Should You Buy, Sell or Hold the Stock?
Bristol Myers growth brands and pipeline progress are boosting momentum, but generic pressure on its legacy portfolio warrants caution.
Will The Recent Pipeline Progress Boost BMY's Portfolio Expansion?
Bristol Myers Squibb's positive arlo-cel data in heavily pretreated multiple myeloma could strengthen its cell therapy pipeline.
Bristol Myers Squibb's Breakout Is Here: Portfolio Renewal Gaining Momentum
Growth assets now comprise 58.2% of Bristol Myers Squibb Company's revenues, with the legacy portfolio also reporting a promising deceleration in top-line erosion cadence. The successful Opdivo/Qvantig conversion and the upcoming launches like iberdomide/mezigdomide target significant multiple myeloma market opportunities. The raised FY2026 guidance and productivity initiatives drive top-line/margin expansion, with the rich cash flows delivering a secure dividend and healthier balance sheet.
Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $66.82, indicating a -1.87% shift from the previous trading day.
Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook?
Bristol Myers??? Camzyos delivers durable five-year benefits, rising sales and potential adolescent label expansion.
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Bristol Myers Squibb: Still Cheap, Despite What The Chart Says
Bristol Myers Squibb remains a Strong Buy, trading at a 51% discount to sector median with a compelling risk/reward profile. BMY's growth portfolio delivered 15% YoY revenue growth, offsetting headwinds from Opdivo's decline and upcoming Eliquis patent expiry. The company boasts a 3.7% forward dividend yield, robust margins, and accelerating bottom-line growth, supporting its defensive, income-generating appeal.
Bristol Myers Squibb: Buy The Growth Portfolio At A Value Price
Bristol Myers Squibb remains undervalued, trading at a 9.8x forward P/E with a 3.7% yield. BMY's growth portfolio now drives nearly 60% of revenue, offsetting legacy drug declines and supporting 5% YoY total revenue growth. Management raised full-year adjusted EPS guidance, with robust Eliquis growth and a strong pipeline of over 10 potential new medicines.
Can Camzyos' Growth Offset Bristol Myers' Patent Pressures?
BMY's Camzyos gains momentum as an adolescent expansion nears an FDA decision, while rivals advance competing heart drugs.
Can Eliquis Cushion Bristol Myers' Legacy Portfolio Erosion?
BMY's legacy portfolio faces generic pressure, but stronger Eliquis sales prompt a brighter 2026 revenue outlook.
Here's Why Bristol Myers Squibb (BMY) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
